The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Stopped A business decision due to availability of commercial drug and other options for accessing study drug treatment.
Conditions
Interventions
- DRUG: Pemigatinib
- DRUG: Retifanlimab
- DRUG: Pembrolizumab
Sponsor
Incyte Corporation